Concerning HR+/HER2− metastatic BC, a phase Ib trial tested the safety and preliminary efficiency of the association of ribociclib (continuous versus discontinuous) and fulvestrant, with/without alpelisib or buparlisib. Here, HR is linked to breast cancer.